European Heart Journal Valvular and Structural Heart Disease · Jul 9, 2026
Identification of undiagnosed valvular heart disease in the community using routine healthcare data: systematic review and meta-analysis
By Helbitz A, Ginks W, Haris M et al.
BACKGROUND AND AIMS: Valvular heart disease (VHD) conveys a high burden of morbidity and mortality and, given the increasing armamentarium of therapeutic interventions, earlier diagnosis is important.This meta-analysis aimed to evaluate the potential of tools in routine health data to identify individuals with undiagnosed VHD in community or population-based settings. METHODS: MEDLINE and Embase were searched from inception to 6 October 2025, for studies describing tools derived, validated or augmented to identify VHD in community populations. Potential measures (C-statistics) were pooled using Bayesian meta-analysis stratified by valve class and data modality with potential data from ≥3 cohorts, with heterogeneity assessed using 95% prediction intervals. Risk of bias was evaluated using the Prediction model Risk Of Bias Assessment Tool (PROBAST). RESULTS: Nineteen studies including 33 prediction tools were included; 18% had a high risk of bias. Imaging- and electrocardiogram-based models demonstrated excellent potential [C-statistic 0.861 (95% CI 0.827-0.889; I ² = 96%) and 0.830 (0.802-0.855; I ² = 100%)], while multivariable clinical models displayed good potential and biomarker-based models adequate potential [0.786 (0.663-0.872; I ² = 99%) and 0.699 (0.629-0.760; I ² = 0%)]. Models targeting right-sided and mitral valve disease showed excellent potential [0.885 (0.837-0.920; I ² = 98%), 0.851 (0.819-0.879; I ² = 99%)]. Models targeting aortic valve disease displayed good potential [0.797 (0.765-0.826; I ² = 100%)]. External validation was limited, only one study assessed clinical utility, and no study prospectively validated a model. CONCLUSIONS: Models using routine healthcare data to identify risk of undiagnosed VHD show potential but comprehensive external and prospective validation is required before consideration of implementation.
doi.org/10.1093/ehjvshd/xwag056Open accessPubMed 43053863Biomarkers